IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)

The date from the date of birth to the date of pathological diagnosis (Years)

Pathological tumoral size after partial or complete surgery

Pathological size in millimeters after complete surgery

Presence of metastasis on complete lymphadenectomy

Clinical measurement of the tumor in millimeters after surgery

Presence of axillary lymph nodes before surgery (no versus yes)

Expression of estrogen receptors on tumor after surgery (% expression in immuno-histo-chemistry, ranging from 0 to 100%.

Expression of progesterone receptor on tumor after surgery (% expression in immuno-histo-chemistry, ranging from 0 to 100%.

Expression of HER2 on tumor after surgery (expression assessed by immuno-histo-chemistry, if HER2 is ++, fluorescence in situ hybridization. HER2 status is ranged to not overexpressed (0 and +), equivocal (++) and overexpressed (+++).

Male or Female

This grade is the addition of score of tubule formation (>75% 1 point 10%-75% 2 point <10% 3 points), nuclear pleomorphism (small, regular uniform cells 1 point moderate increase in size and variability 2 points, marked Variation 3 points) and mitotic counts (dependent on microscope field area 1-3 points) assessed by pathology analysis on tumor after surgery. The SBR grade is ranging from I (total of 3 to 5), II (6 and 7) and III (8 and 9).

Presence or absence of in situ carcinoma assessed by pathology analysis on tumor after surgery

Histologic subtype of breast tumor : ductal, lobular or other, assessed by pathology analysis on tumor after complete surgery

Metastatic sites of primary breast cancer : Nodal (other than axillary), lung, liver, bone, cerebral and other sites.

Type of chemotherapy (adjuvant, neoadjuvant, metastatic)

The time from the date of first treatment or of first consultation, whichever comes first, to the date of death from any cause.

The time from the date of the first treatment or th first consultation to the date of local or ipsilateral or controlateral invasive breast cancer, or other invasive cancer or distant recurrence or death from breast cancer or any cause

The time from the date of the first treatment or the first consultation to the date of distant recurrence or death from breast cancer or any cause